Variable | Characteristics | Cost after 12 months (€) | ||
---|---|---|---|---|
N | Mean (SD) | P-value | ||
Age (years) | < 30 | 31 | 103,146 (44,270) | 0.6285a |
30 to 50 | 65 | 107,689 (35,434) | ||
> 50 | 112 | 102,125 (36,422) | ||
Sex | F | 87 | 99,375 (33,651) | 0.1282b |
M | 121 | 107,353 (39,485) | ||
Underlying disease | Acute leukemia and myelodysplastic syndrome | 143 | 100,960 (31,157) | 0.2259a |
Lymphoproliferative disorder | 46 | 111,367 (48,575) | ||
Myeloproliferative disorder | 12 | 116,491 (56,018) | ||
Other | 7 | 96,756 (22,709) | ||
Donor type | HLA identical sibling | 83 | 103,795 (41,940) | 0.8294a |
Unrelated donor | 107 | 104,998 (33,467) | ||
Cord blood unit | 18 | 99,200 (37,742) | ||
D/R match | HLA identical sibling | 83 | 103,795 (41,940) | 0.8986a |
Unrelated donor 10/10 and cord blood unit 6/6 | 63 | 102,644 (32,594) | ||
Unrelated donor 9/10 and cord blood unit 4/6 or 5/6 | 62 | 105,706 (35,598) | ||
Stem cell source | Bone marrow | 50 | 99,679 (39,183) | 0.7950a |
Peripheral blood stem cell | 140 | 106,184 (36,604) | ||
Cord blood unit | 18 | 99,200 (37,742) | ||
Conditioning regimen | Reduced intensity | 92 | 108,178 (31,779) | 0.3566a |
Mini | 61 | 101,129 (42,830) | ||
Myeloablative | 55 | 100,256 (39,172) | ||
Recipient CMV serology | R+ | 130 | 103,494 (34,279) | 0.7950b |
R- | 78 | 104,886 (42,030) | ||
Number of CMV episodes | 0 | 138 | 99,793 (39,654) | 0.0214a |
1 | 44 | 104,815 (24,271) | ||
≥2 | 26 | 125,080 (36,290) | ||
Acute graft-versus-host disease | 0 and 1 | 112 | 96,278 (37,441) | 0.0011a |
2 to 4 | 96 | 113,043 (35,180) | ||
Chronic graft-versus-host disease | No | 140 | 101,858 (33,633) | 0.2320b |
Yes | 68 | 108,458 (43,789) | ||
Alive at the end of the mentioned period | No | 80 | 109,067 (29,356) | 0.1227b |
Yes | 128 | 100,859 (41,270) | ||
First CMV infection | ≤100 days | 53 | 109,015 (30,231) | 0.1841 b |
>100 days | 18 | 119,834 (32,142) |